Foghorn Therapeutics (FHTX) Stock Forecast, Price Target & Predictions
FHTX Stock Forecast
Foghorn Therapeutics stock forecast is as follows: an average price target of $14.00 (represents a 172.37% upside from FHTX’s last price of $5.14) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
FHTX Price Target
The average price target for Foghorn Therapeutics (FHTX) is $14.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $9.00. This represents a potential 172.37% upside from FHTX's last price of $5.14.
FHTX Analyst Ratings
According to 5 Wall Street analysts, Foghorn Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for FHTX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Foghorn Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 17, 2024 | Foghorn Therapeutics to $ | H.C. Wainwright | $13.00 | $6.26 | 107.67% | 152.92% |
| Sep 24, 2024 | Vikram Purohit | Morgan Stanley | $9.00 | $9.32 | -3.43% | 75.10% |
| Aug 19, 2024 | Gavin Clark-Gartner | Evercore ISI | $20.00 | $6.26 | 219.49% | 289.11% |
| Jan 05, 2023 | BMO Capital | $20.00 | $6.53 | 206.28% | 289.11% | |
| Nov 21, 2022 | Morgan Stanley | $14.00 | $7.87 | 77.89% | 172.37% | |
| Aug 23, 2022 | Vikram Purohit | Morgan Stanley | $15.00 | $10.89 | 37.74% | 191.83% |
The latest Foghorn Therapeutics stock forecast, released on Dec 17, 2024 by Foghorn Therapeutics to $ from H.C. Wainwright, set a price target of $13.00, which represents a 107.67% increase from the stock price at the time of the forecast ($6.26), and a 152.92% increase from FHTX last price ($5.14).
Foghorn Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 3 |
| Avg Price Target | $13.00 | $11.00 | $14.00 |
| Last Closing Price | $5.14 | $5.14 | $5.14 |
| Upside/Downside | 152.92% | 114.01% | 172.37% |
In the current month, the average price target of Foghorn Therapeutics stock is $13.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 152.92% increase as opposed to Foghorn Therapeutics's last price of $5.14. This month's average price target is up 18.18% compared to last quarter, and down -7.14% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 24, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Sep 03, 2024 | Jefferies | Buy | Initialise | |
| Aug 19, 2024 | Evercore ISI | Outperform | Initialise | |
| Jun 29, 2023 | Goldman Sachs | Buy | Buy | Hold |
| Jan 05, 2023 | BMO Capital | Outperform | Initialise | |
| Nov 21, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Aug 23, 2022 | Morgan Stanley | Overweight | Hold | Downgrade |
| May 23, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
Foghorn Therapeutics's last stock rating was published by Morgan Stanley on Sep 24, 2024. The company gave FHTX a "Equal-Weight" rating, the same as its previous rate.
Foghorn Therapeutics Financial Forecast
Foghorn Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $17.48M | $5.60M | $5.31M | $4.18M | $6.63M | $4.49M | $3.92M | $713.00K | $41.00K | $279.00K | $286.00K | $251.00K | $179.00K |
| Avg Forecast | $11.23M | $5.93M | $5.78M | $5.64M | $7.13M | $6.34M | $6.04M | $6.91M | $4.54M | $4.58M | $6.32M | $5.04M | $8.48M | $9.19M | $9.58M | $9.43M | $709.75K | $30.75K | $279.00K | $190.67K | $500.00K | $626.33K |
| High Forecast | $11.48M | $6.06M | $5.91M | $5.74M | $14.45M | $6.37M | $6.04M | $7.06M | $6.94M | $4.68M | $6.46M | $5.15M | $8.66M | $9.19M | $9.58M | $9.43M | $709.75K | $30.75K | $279.00K | $190.67K | $500.00K | $626.33K |
| Low Forecast | $11.03M | $5.82M | $5.68M | $5.53M | $4.58M | $6.30M | $6.04M | $6.79M | $1.49M | $4.50M | $6.21M | $4.95M | $8.33M | $9.19M | $9.58M | $9.43M | $709.75K | $30.75K | $279.00K | $190.67K | $500.00K | $626.33K |
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.81% | 0.89% | 1.05% | 0.49% | 0.72% | 0.47% | 0.42% | 1.00% | 1.33% | 1.00% | 1.50% | 0.50% | 0.29% |
Foghorn Therapeutics's average Quarter revenue forecast for Dec 23 based on 4 analysts is $4.54M, with a low forecast of $1.49M, and a high forecast of $6.94M. FHTX's average Quarter revenue forecast represents a -74.01% decrease compared to the company's last Quarter revenue of $17.48M (Sep 23).
Foghorn Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-17.08M | $-31.17M | $-33.32M | $-37.14M | $-24.93M | $-26.49M | $-26.10M | $70.59M | $-24.72M | $-21.83M | $-21.73M | $1.06M | $236.51K |
| Avg Forecast | $-6.74M | $-3.56M | $-3.47M | $-3.38M | $-4.28M | $-3.80M | $-3.62M | $-4.15M | $-2.73M | $-2.75M | $-3.79M | $-3.02M | $-5.09M | $-5.51M | $-5.75M | $-5.66M | $-425.85K | $-18.45K | $-167.40K | $-22.07M | $-300.00K | $-375.80K |
| High Forecast | $-6.62M | $-3.49M | $-3.41M | $-3.32M | $-2.75M | $-3.78M | $-3.62M | $-4.07M | $-893.76K | $-2.70M | $-3.73M | $-2.97M | $-5.00M | $-5.51M | $-5.75M | $-5.66M | $-425.85K | $-18.45K | $-167.40K | $-17.66M | $-300.00K | $-375.80K |
| Low Forecast | $-6.89M | $-3.64M | $-3.54M | $-3.44M | $-8.67M | $-3.82M | $-3.62M | $-4.24M | $-4.16M | $-2.81M | $-3.88M | $-3.09M | $-5.20M | $-5.51M | $-5.75M | $-5.66M | $-425.85K | $-18.45K | $-167.40K | $-26.49M | $-300.00K | $-375.80K |
| Surprise % | - | - | - | - | - | - | - | - | - | 6.21% | 8.22% | 11.02% | 7.30% | 4.52% | 4.61% | 4.61% | -165.77% | 1339.84% | 130.42% | 0.98% | -3.52% | -0.63% |
1 analysts predict FHTX's average Quarter EBITDA for Mar 22 to be $-5.66M, with a high of $-5.66M and a low of $-5.66M. This is -108.01% lower than Foghorn Therapeutics's previous annual EBITDA (Dec 21) of $70.59M.
Foghorn Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | $-14.35M | $-29.49M | $-30.49M | $-34.13M | $-23.28M | $-25.44M | $-26.02M | $170.75M | $-26.08M | $-23.11M | $-22.99M | $-68.80K | - |
| Avg Forecast | $-20.35M | $-26.29M | $-26.29M | $-26.08M | $-20.45M | $-26.92M | $-39.91M | $-39.65M | $-46.58M | $-43.82M | $-44.45M | $-44.29M | $-37.19M | $-29.53M | $-29.53M | $-27.08M | $-38.27M | $-34.82M | $-31.46M | $-23.35M | $-21.79M | $-157.15M |
| High Forecast | $-19.87M | $-25.68M | $-25.68M | $-23.85M | $-15.83M | $-26.30M | $-38.98M | $-38.73M | $-37.14M | $-42.81M | $-43.42M | $-43.26M | $-36.32M | $-29.53M | $-29.53M | $-27.08M | $-38.27M | $-34.82M | $-31.46M | $-18.68M | $-21.79M | $-157.15M |
| Low Forecast | $-20.92M | $-27.03M | $-27.03M | $-27.58M | $-23.75M | $-27.68M | $-41.03M | $-40.77M | $-55.42M | $-45.06M | $-45.70M | $-45.54M | $-38.23M | $-29.53M | $-29.53M | $-27.08M | $-38.27M | $-34.82M | $-31.46M | $-28.02M | $-21.79M | $-157.15M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.33% | 0.66% | 0.69% | 0.92% | 0.79% | 0.86% | 0.96% | -4.46% | 0.75% | 0.73% | 0.98% | 0.00% | - |
Foghorn Therapeutics's average Quarter net income forecast for Mar 22 is $-27.08M, with a range of $-27.08M to $-27.08M. FHTX's average Quarter net income forecast represents a -115.86% decrease compared to the company's last Quarter net income of $170.75M (Dec 21).
Foghorn Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | $8.31M | $8.40M | $8.64M | $7.86M | $7.96M | $7.70M | $7.22M | $-15.37M | $5.81M | $4.90M | $4.69M | $4.56M | $2.56M |
| Avg Forecast | $103.73M | $54.76M | $53.37M | $52.05M | $65.80M | $58.54M | $55.78M | $63.81M | $41.95M | $42.32M | $58.41M | $46.52M | $78.29M | $84.56M | $88.21M | $86.80M | $6.53M | $283.03K | $2.57M | $1.75M | $4.60M | $5.76M |
| High Forecast | $105.98M | $55.95M | $54.53M | $52.97M | $133.45M | $58.85M | $55.78M | $65.20M | $64.08M | $43.24M | $59.67M | $47.53M | $79.99M | $84.56M | $88.21M | $86.80M | $6.53M | $283.03K | $2.57M | $1.75M | $4.60M | $5.76M |
| Low Forecast | $101.88M | $53.79M | $52.42M | $51.06M | $42.28M | $58.22M | $55.78M | $62.67M | $13.76M | $41.57M | $57.36M | $45.69M | $76.90M | $84.56M | $88.21M | $86.80M | $6.53M | $283.03K | $2.57M | $1.75M | $4.60M | $5.76M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.20% | 0.14% | 0.19% | 0.10% | 0.09% | 0.09% | 0.08% | -2.35% | 20.52% | 1.91% | 2.67% | 0.99% | 0.44% |
Foghorn Therapeutics's average Quarter SG&A projection for Dec 23 is $41.95M, based on 4 Wall Street analysts, with a range of $13.76M to $64.08M. The forecast indicates a 404.95% rise compared to FHTX last annual SG&A of $8.31M (Sep 23).
Foghorn Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.34 | $-0.70 | $-0.73 | $-0.82 | $-0.56 | $-0.61 | $-0.63 | $4.62 | $-0.71 | $-0.63 | $-0.62 | $-0.00 | $-0.51 |
| Avg Forecast | $-0.33 | $-0.42 | $-0.42 | $-0.42 | $-0.33 | $-0.43 | $-0.64 | $-0.63 | $-0.74 | $-0.70 | $-0.71 | $-0.71 | $-0.59 | $-0.57 | $-0.57 | $-0.53 | $-0.74 | $-0.68 | $-0.61 | $-0.60 | $-0.42 | $-3.05 |
| High Forecast | $-0.32 | $-0.41 | $-0.41 | $-0.38 | $-0.25 | $-0.42 | $-0.62 | $-0.62 | $-0.59 | $-0.68 | $-0.69 | $-0.69 | $-0.58 | $-0.57 | $-0.57 | $-0.53 | $-0.74 | $-0.68 | $-0.61 | $-0.60 | $-0.42 | $-3.05 |
| Low Forecast | $-0.33 | $-0.43 | $-0.43 | $-0.44 | $-0.38 | $-0.44 | $-0.66 | $-0.65 | $-0.89 | $-0.72 | $-0.73 | $-0.73 | $-0.61 | $-0.57 | $-0.57 | $-0.53 | $-0.74 | $-0.68 | $-0.61 | $-0.60 | $-0.42 | $-3.05 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.49% | 0.99% | 1.03% | 1.38% | 0.98% | 1.07% | 1.20% | -6.23% | 1.05% | 1.03% | 1.03% | 0.01% | 0.17% |
According to 1 Wall Street analysts, Foghorn Therapeutics's projected average Quarter EPS for Mar 22 is $-0.53, with a low estimate of $-0.53 and a high estimate of $-0.53. This represents a -111.36% decrease compared to FHTX previous annual EPS of $4.62 (Dec 21).
Foghorn Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| STTK | Shattuck Labs | $1.15 | $12.00 | 943.48% | Hold |
| MOLN | Molecular Partners | $5.25 | $29.00 | 452.38% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| PRLD | Prelude Therapeutics | $0.89 | $4.00 | 349.44% | Sell |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| FHTX | Foghorn Therapeutics | $5.51 | $14.00 | 154.08% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| NRIX | Nurix Therapeutics | $21.18 | $32.67 | 54.25% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| RZLT | Rezolute | $4.44 | $6.67 | 50.23% | Buy |
| KYMR | Kymera Therapeutics | $42.30 | $58.60 | 38.53% | Buy |